Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Jiangsu, 221002, PR China; Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Jiangsu, 221002, PR China.
Department of Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Aachen, 52074, Germany.
Biomaterials. 2021 Jan;267:120483. doi: 10.1016/j.biomaterials.2020.120483. Epub 2020 Oct 26.
Metal ions imbalance, a well-established pathologic feature of alzheimer's disease (AD), ultimately results in the deposition of amyloid-β peptide (Aβ) proteins and Aβ-induced neurotoxicity. Herein, to overcome these hurdles, an intelligent Aβ nanocaptor with the capacity to chelate metal ions and targeted therapy is developed by anchoring carbon nitride (CN) nanodots to FeO@mesoporous silica nanospheres, and decorated with benzothiazole aniline (BTA) (designated as B-FeCN). The CN nanodots could effectively capture superfluous Cu to suppress the formation of Cu-Aβ complex thereby eliminating Aβ aggregation. Simultaneously, the nanocaptor enables local low-temperature hyperthermia to promote the dissolution of preformed fiber precipitates, therefore, maximizing the therapeutic benefits. Owing to its favorable photothermal effect, the blood-brain barrier (BBB) permeability of the nanocaptor is noticeably ameliorated upon laser illumination, which conquers the limitations associated with traditional anti-AD drugs, as evidenced by in vivo and in vitro studies. Besides, leveraging on the magnetic properties of FeO core, the nanocaptor is magnetized to access to the targeted Aβ regions under extrinsic magnetic field. BTA conjugation, which specifically binds to the β position of the Aβ fibers, executes specific targeting at Aβ plaques, and synchronously endows the BTA-modified nanocaptor with fluorescent imaging property for sensitively detecting Aβ aggregates. In view of these superiorities, nanocaptors combine metallostasis restoration and Aβ targeted therapy can surmount the interference of copper ions, enhance BBB permeability and protect cells against Aβ-induced neurotoxicity, which provides new avenues for developing neuroprotective nanosystems for the treatment of alzheimer's disease.
金属离子失衡是阿尔茨海默病(AD)的一个明确的病理特征,最终导致淀粉样β肽(Aβ)蛋白的沉积和 Aβ诱导的神经毒性。在此,为了克服这些障碍,通过将氮化碳(CN)纳米点锚定到 FeO@介孔硅纳米球上,并通过苯并噻唑苯胺(BTA)进行修饰,开发了一种具有螯合金属离子和靶向治疗能力的智能 Aβ纳米捕获器(命名为 B-FeCN)。CN 纳米点可以有效地捕获多余的 Cu,以抑制 Cu-Aβ 配合物的形成,从而消除 Aβ 聚集。同时,纳米捕获器可以实现局部低温热疗,以促进预形成纤维沉淀物的溶解,从而最大限度地发挥治疗效果。由于其良好的光热效应,纳米捕获器在激光照射下显著改善了血脑屏障(BBB)的通透性,克服了传统抗 AD 药物的局限性,这在体内和体外研究中得到了证实。此外,利用 FeO 核的磁性,纳米捕获器在外磁场的作用下被磁化到靶向的 Aβ 区域。BTA 缀合,特异性结合在 Aβ 纤维的β位置,对 Aβ 斑块进行特异性靶向,同时赋予 BTA 修饰的纳米捕获器荧光成像特性,用于灵敏检测 Aβ 聚集物。鉴于这些优势,纳米捕获器结合金属稳态恢复和 Aβ 靶向治疗可以克服铜离子的干扰,提高 BBB 的通透性,并保护细胞免受 Aβ 诱导的神经毒性,为开发用于治疗阿尔茨海默病的神经保护纳米系统提供了新途径。